BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2026.
World J Gastroenterol. Feb 14, 2026; 32(6): 115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Figure 2
Figure 2 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups after propensity score matching. A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval. AC: Adjuvant chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy; HR: Hazard ratio.


Write to the Help Desk